Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia

[1]  A. Rauf,et al.  A comprehensive review of the health perspectives of resveratrol. , 2017, Food & function.

[2]  Javed Ali,et al.  Resveratrol: review on therapeutic potential and recent advances in drug delivery , 2014, Expert opinion on drug delivery.

[3]  M. Bordbar,et al.  Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients , 2014, Iranian Red Crescent medical journal.

[4]  D. Sinclair,et al.  Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice , 2014, Haematologica.

[5]  Giannis Tzimas,et al.  Updates of the HbVar database of human hemoglobin variants and thalassemia mutations , 2013, Nucleic Acids Res..

[6]  J. Blodgett,et al.  Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders , 2013, BMJ Open.

[7]  K. Brown,et al.  Resveratrol in the management of human cancer: how strong is the clinical evidence? , 2013, Annals of the New York Academy of Sciences.

[8]  Rajiv Gupta,et al.  Bioavailability enhancers of herbal origin: an overview. , 2013, Asian Pacific Journal of Tropical Biomedicine.

[9]  M. Karimi,et al.  Induction of HBF , 2013 .

[10]  M. Cappellini,et al.  Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. , 2013, Blood.

[11]  M. Shahjahani,et al.  Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders , 2013, International journal of hematology-oncology and stem cell research.

[12]  C. Modi,et al.  A Comprehensive Review on Pharmacotherapeutics of Herbal Bioenhancers , 2012, TheScientificWorldJournal.

[13]  Roberto Gambari,et al.  Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients. , 2012, International journal of molecular medicine.

[14]  L. Tütüncü,et al.  Increasing the Stimulation Dose of rFSH in Unexpected Poor Responders Is Not Associated with Better IVF Outcome , 2012 .

[15]  H. Mukhtar,et al.  Enhancing the bioavailability of resveratrol by combining it with piperine. , 2011, Molecular nutrition & food research.

[16]  J. Pezzuto,et al.  What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol , 2011, PloS one.

[17]  Khaled M Musallam,et al.  Optimal management of β thalassaemia intermedia , 2011, British journal of haematology.

[18]  T. Walle.  Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[19]  Karen Brown,et al.  Clinical trials of resveratrol , 2011, Annals of the New York Academy of Sciences.

[20]  Ananda Sen,et al.  Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. , 2010, Cancer research.

[21]  O. Blin,et al.  Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases , 2010, Orphanet Journal of Rare Diseases.

[22]  Jessica A. Miller,et al.  Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study , 2010, Cancer Prevention Research.

[23]  D. Faller,et al.  Fetal globin gene inducers: novel agents and new potential , 2010, Annals of the New York Academy of Sciences.

[24]  Neeraj Singhal,et al.  Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects , 2010, Clinical pharmacokinetics.

[25]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[26]  M. Karimi,et al.  Echocardiographic finding in beta‐thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta‐thalassemia intermedia , 2009, European journal of haematology.

[27]  U. Testa.  Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies , 2009, Annals of Hematology.

[28]  O. Platt,et al.  Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.

[29]  J. Crowell,et al.  Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent , 2007, Cancer Epidemiology Biomarkers & Prevention.

[30]  Roberto Gambari,et al.  Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. , 2007, Current medicinal chemistry.

[31]  M. Karimi,et al.  Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran , 2005, Journal of pediatric hematology/oncology.

[32]  E. Rachmilewitz,et al.  MEDICAL PROGRESS : β-thalassemia , 2005 .

[33]  D. Yee,et al.  Insulin-like growth factor-I and cancer risk. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[34]  P. Romeo,et al.  Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation , 2001, British journal of haematology.

[35]  R. Baxter,et al.  The IGF axis and programmed cell death , 1999, Immunology and cell biology.

[36]  D. Loukopoulos,et al.  Hydroxyurea Therapy in Thalassemia a , 1998, Annals of the New York Academy of Sciences.

[37]  Z. Gardner,et al.  American Herbal Products Association's botanical safety handbook , 1997 .

[38]  A. Schechter,et al.  Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis , 1995 .

[39]  H. Pearson,et al.  Pharmacologic treatment of thalassemia intermedia with hydroxyurea. , 1994, The Journal of pediatrics.